Hysterectomy doesn’t mitigate ovarian cancer risk in Black women with endometriosis, Fred Hutch study shows

Fred Hutch opens science learning lab for students

Fred Hutchinson Cancer Center is opening a new science education lab on its South Lake Union campus, supported by Alexandria Real Estate Equities Inc.

May 30, 2025

Vol.51 No.21

Drugs & Targets

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer

FDA has approved Avmapki Fakzynja Co-Pack (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who received prior systemic therapy. Avmapki Fakzynja Co-Pack is the first and only FDA-approved medicine for this disease.

May 23, 2025

Vol.51 No.20

Drugs & Targets

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.

May 09, 2025

Vol.51 No.18

Clinical Roundup

Heated intraperitoneal chemotherapy associated with longer survival in ovarian cancer

Physicians at Tampa General Hospital and USF Health Morsani College of Medicine conducted a multicenter, retrospective cohort study and found that a highly specialized treatment—heated intraperitoneal chemotherapy delivered directly into the abdominal cavity, is associated with longer survival for women with metastatic epithelial ovarian cancer.

April 18, 2025

Vol.51 No.15

In the Archives

Don Thomas’s “secret weapons”—and how a 1970s BMT database continues to lead to new findings

In the 1970s, when E. Donnall Thomas was researching bone marrow transplantation, Fred Hutchinson Cancer Center started a database of transplant recipients.

April 11, 2025

Vol.51 No.14

In Brief

Filippo Milano named inaugural Endowed Chair in Cord Blood Research at Fred Hutch

Filippo Milano, a hematologist-oncologist and clinical researcher, was named the inaugural Endowed Chair in Cord Blood Research at Fred Hutchinson Cancer Center.

April 11, 2025

Vol.51 No.14

Hysterectomy doesn’t mitigate ovarian cancer risk in Black women with endometriosis, Fred Hutch study shows

YOU MAY BE INTERESTED IN

Fred Hutch opens science learning lab for students

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

Heated intraperitoneal chemotherapy associated with longer survival in ovarian cancer

Don Thomas’s “secret weapons”—and how a 1970s BMT database continues to lead to new findings

Filippo Milano named inaugural Endowed Chair in Cord Blood Research at Fred Hutch

Renew today!

Subscriber content

Never miss an issue!

Login